Cargando…

578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy

BACKGROUND: Although chimeric antigen receptor T cells (CAR-T) is a promising novel therapy for the treatment of relapsed or refractory (R/R) B-cell malignancies, data on infectious complications associated with this therapy are limited. Therefore, further assessment of infections after CAR-T therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Nikki, Eschenauer, Gregory, Scappaticci, Gianni, Frame, David, Miceli, Marisa H, Patel, Twisha S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777222/
http://dx.doi.org/10.1093/ofid/ofaa439.772
_version_ 1783630852170711040
author Tran, Nikki
Eschenauer, Gregory
Scappaticci, Gianni
Frame, David
Miceli, Marisa H
Patel, Twisha S
author_facet Tran, Nikki
Eschenauer, Gregory
Scappaticci, Gianni
Frame, David
Miceli, Marisa H
Patel, Twisha S
author_sort Tran, Nikki
collection PubMed
description BACKGROUND: Although chimeric antigen receptor T cells (CAR-T) is a promising novel therapy for the treatment of relapsed or refractory (R/R) B-cell malignancies, data on infectious complications associated with this therapy are limited. Therefore, further assessment of infections after CAR-T therapy is warranted. METHODS: We retrospectively reviewed and analyzed infectious complications for 6 months following CAR-T therapy infusion (CTI) in 39 adult and pediatric patients with R/R acute lymphoblastic leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) at Michigan Medicine. RESULTS: Overall, 20 infections were identified in 16 of 39 patients (41%) following CTI [detailed in Table 1]; 8 (40%) infections occurred in the early period (Day 0–30) and 12 (60%) infections occurred during late period (Day 31–180). The most common infections were viral (n=10, 50%; 80% of viral infections were respiratory viruses), followed by 8 bacterial infections (40%), and 2 fungal infections (10%). More bacterial infections were seen in the early period post-CTI (30% vs. 10%, p = 0.019), whereas viral infections were more common during the late period (40% vs. 10%, p = 0.68). Antimicrobial prophylaxis prior to CTI and following CTI were similar (Table 2). The majority of patients included in the study had NHL (n=32, 82%). Mean age of the cohort was 52 ± 22 years, and 64% were male. 85% of the population developed cytokine release syndrome (CRS) with 67% grade 1–2 and 18% grade 3–5. As shown in Table 2, most baseline characteristics were similar between patients with and without infections post CTI except infected patients were older (63.3 ± 11.3 vs. 44.8 ± 24.2, p = 0.01) and more received steroids for CRS (56% vs 17%, p = 0.02). All-cause mortality within 6 months following CTI was similar in infected and uninfected groups (38% vs 26%, p= 0.50). Table 1 [Image: see text] Table 2 [Image: see text] CONCLUSION: Infectious complications are common following CAR-T therapy. We found the majority of infections to be caused by various bacteria or respiratory viruses in a cohort of patients with lymphoma as the most common underlying malignancy. DISCLOSURES: Marisa H. Miceli, MD, FIDSA, SCYNEXIS, Inc. (Advisor or Review Panel member)
format Online
Article
Text
id pubmed-7777222
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77772222021-01-07 578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy Tran, Nikki Eschenauer, Gregory Scappaticci, Gianni Frame, David Miceli, Marisa H Patel, Twisha S Open Forum Infect Dis Poster Abstracts BACKGROUND: Although chimeric antigen receptor T cells (CAR-T) is a promising novel therapy for the treatment of relapsed or refractory (R/R) B-cell malignancies, data on infectious complications associated with this therapy are limited. Therefore, further assessment of infections after CAR-T therapy is warranted. METHODS: We retrospectively reviewed and analyzed infectious complications for 6 months following CAR-T therapy infusion (CTI) in 39 adult and pediatric patients with R/R acute lymphoblastic leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) at Michigan Medicine. RESULTS: Overall, 20 infections were identified in 16 of 39 patients (41%) following CTI [detailed in Table 1]; 8 (40%) infections occurred in the early period (Day 0–30) and 12 (60%) infections occurred during late period (Day 31–180). The most common infections were viral (n=10, 50%; 80% of viral infections were respiratory viruses), followed by 8 bacterial infections (40%), and 2 fungal infections (10%). More bacterial infections were seen in the early period post-CTI (30% vs. 10%, p = 0.019), whereas viral infections were more common during the late period (40% vs. 10%, p = 0.68). Antimicrobial prophylaxis prior to CTI and following CTI were similar (Table 2). The majority of patients included in the study had NHL (n=32, 82%). Mean age of the cohort was 52 ± 22 years, and 64% were male. 85% of the population developed cytokine release syndrome (CRS) with 67% grade 1–2 and 18% grade 3–5. As shown in Table 2, most baseline characteristics were similar between patients with and without infections post CTI except infected patients were older (63.3 ± 11.3 vs. 44.8 ± 24.2, p = 0.01) and more received steroids for CRS (56% vs 17%, p = 0.02). All-cause mortality within 6 months following CTI was similar in infected and uninfected groups (38% vs 26%, p= 0.50). Table 1 [Image: see text] Table 2 [Image: see text] CONCLUSION: Infectious complications are common following CAR-T therapy. We found the majority of infections to be caused by various bacteria or respiratory viruses in a cohort of patients with lymphoma as the most common underlying malignancy. DISCLOSURES: Marisa H. Miceli, MD, FIDSA, SCYNEXIS, Inc. (Advisor or Review Panel member) Oxford University Press 2020-12-31 /pmc/articles/PMC7777222/ http://dx.doi.org/10.1093/ofid/ofaa439.772 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Tran, Nikki
Eschenauer, Gregory
Scappaticci, Gianni
Frame, David
Miceli, Marisa H
Patel, Twisha S
578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy
title 578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy
title_full 578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy
title_fullStr 578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy
title_full_unstemmed 578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy
title_short 578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy
title_sort 578. infections in patients treated with chimeric antigen receptor t-cells (car-t) therapy
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777222/
http://dx.doi.org/10.1093/ofid/ofaa439.772
work_keys_str_mv AT trannikki 578infectionsinpatientstreatedwithchimericantigenreceptortcellscarttherapy
AT eschenauergregory 578infectionsinpatientstreatedwithchimericantigenreceptortcellscarttherapy
AT scappaticcigianni 578infectionsinpatientstreatedwithchimericantigenreceptortcellscarttherapy
AT framedavid 578infectionsinpatientstreatedwithchimericantigenreceptortcellscarttherapy
AT micelimarisah 578infectionsinpatientstreatedwithchimericantigenreceptortcellscarttherapy
AT pateltwishas 578infectionsinpatientstreatedwithchimericantigenreceptortcellscarttherapy